KLOW Blend
البحوث المنشورة وقاعدة الأدلة
KLOW is a marketed combination of four peptides: BPC-157, TB-500 (a fragment-based thymosin beta-4 analogue), GHK-Cu and KPV. A systematic search of PubMed and Europe PMC returned no published study of this four-peptide blend in any model, and no pharmacokinetic, efficacy or safety data exist for the combination. The available literature is component-level: BPC-157 rests almost entirely on rodent work from a small number of laboratories with only two very small uncontrolled human pilot studies; thymosin beta-4 has two randomised phase 2 wound trials; KPV is supported by in vitro and animal anti-inflammatory work; and GHK-Cu is covered separately in this dataset. Only one published study examines any two of the components together.
- KLOW Blend هو مزيج مسوق من أربعة ببتيدات: BPC-157 و TB-500 و GHK-Cu و KPV.
- لم تختبر أي دراسة منشورة هذا المزيج الرباعي من الببتيدات في أي نموذج.
- أدلة المكونات تأتي في الغالب من دراسات حيوانية أو خلوية وليست تجارب بشرية محكمة.
18 دراسة · 11 منذ 2023 · الأحدث 2026
- الدراسات المذكورة
- 18
- منشورة 2023+
- 11
- أحدث ورقة بحثية
- 2026
- آخر مراجعة
- أكتوبر 2026
المواضيع المتكررة في الأدبيات
- component-level evidence only
- no blend pharmacokinetics
- angiogenesis and granulation tissue formation
- actin sequestration and cell migration
- alpha-MSH-derived anti-inflammatory tripeptide
- unapproved injectable peptides in sports medicine
- compounded peptide quality and regulatory status
18 دراسة منشورة.
مرتبة حسب قوة تصميم الدراسة، ثم حسب الحداثة. كل إدخال يرتبط بالسجل المصدري حتى يمكن التحقق من النتيجة مقابل الورقة البحثية بدلاً من الاعتماد على كلامنا.
- 01مراجعة منهجية2025
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
Vasireddi N, et al. · HSS Journal · systematic review of BPC-157 literature relevant to orthopaedic sports medicine
The review systematically collated the BPC-157 evidence base for musculoskeletal applications. It provides the most structured appraisal available of how much of that base is preclinical.
- 02سريري بشري2025
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.
Lee E, et al. · Alternative Therapies in Health and Medicine · IRB-approved pilot, n=2 participants, 10 mg then 20 mg BPC-157 in 250 cc normal saline infused over one hour on consecutive days, private clinic
Two participants received intravenous BPC-157 with baseline and post-infusion bloods and vital signs. With n=2 and no control arm, the study cannot establish safety; the authors noted that few human studies of BPC-157 exist and none previously on intravenous use.
نتيجة سلامة مُبلغ عنها. Only published human safety data for intravenous BPC-157; sample size of two makes it uninformative about risk.
- 03سريري بشري2025
Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion.
Zhang Y, et al. · Cardiovasc Res · mouse ischaemia-reperfusion and permanent-ligation models plus randomised double-blind placebo-controlled trial, n=96 STEMI patients after PCI
In mice recombinant human thymosin beta-4 reduced cardiac dysfunction, fibrosis and infarct size through ErbB2 signalling. In the trial, infarct area was reduced in patients dosed within 8 hours of PCI, but the overall difference between treatment and placebo groups was not significant. This study used full-length thymosin beta-4, not the TB-500 fragment (Ac-LKKTETQ).
- 04سريري بشري2024
Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.
Lee E, et al. · Alternative Therapies in Health and Medicine · uncontrolled pilot, n=12 women aged 39-76 (mean 58.3), BPC-157 from a 503A compounding pharmacy, private clinic
Twelve women with interstitial cystitis received compounded BPC-157 in an open-label pilot. The authors stated that BPC-157 is not FDA-approved; there was no placebo arm and the product was compounded rather than pharmaceutical grade.
نتيجة سلامة مُبلغ عنها. Study product was supplied by a compounding pharmacy; BPC-157 has no FDA approval.
- 05سريري بشري2021
Recombinant human thymosin beta-4 (rhTb4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis.
Yu R, et al. · Microbial Biotechnology · human scalp study in seborrheic dermatitis with scalp microbiome profiling
Recombinant human thymosin beta-4 was associated with improved scalp condition and scalp microbiome homeostasis in seborrheic dermatitis. It is one of very few human cutaneous datasets for a thymosin beta-4 product. This study used full-length thymosin beta-4, not the TB-500 fragment (Ac-LKKTETQ).
- 06سريري بشري2010
The effect of thymosin treatment of venous ulcers.
Guarnera G, et al. · Annals of the New York Academy of Sciences · double-blind, placebo-controlled, dose-escalation phase 2 trial, n=73 randomised across eight European sites (five Italy, three Poland)
Topical thymosin beta-4 was assessed for safety, tolerability and efficacy in venous stasis ulcers; the safety profile of all administered doses was deemed acceptable. This is the highest-tier human evidence for any KLOW component other than GHK-Cu. This study used full-length thymosin beta-4, not the TB-500 fragment (Ac-LKKTETQ).
- 07سريري بشري2010
A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers.
Ruff D, et al. · Ann N Y Acad Sci · phase 1 randomised placebo-controlled single and 14-day multiple ascending-dose study, 4 cohorts of 10 healthy volunteers, intravenous synthetic thymosin beta-4
Adverse events were infrequent and mild or moderate, with no dose-limiting toxicities or serious adverse events. Pharmacokinetics were dose-proportional, with half-life increasing at higher doses. This study used full-length thymosin beta-4, not the TB-500 fragment (Ac-LKKTETQ).
- 08حيواني داخل الجسم الحي2026
Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.
Bicer O, et al. · Joint Diseases and Related Surgery · 32 male Sprague-Dawley rats, Achilles tendon transection and repair, four groups (control, BPC-157 10 ug/kg/day, TB-500 60 ug/kg/day, combination), intraperitoneal dosing for 4 weeks
This is the only located study administering two KLOW components together. Tendons were assessed by maximum load to failure and by histological, histochemical and immunohistochemical analysis at four weeks. It concerns tendon rather than skin and does not include GHK-Cu or KPV.
- 09حيواني داخل الجسم الحي2026
Low-Temperature Fabrication of Thymosin b4-Loaded Soluble Microneedles to Promote Wound Healing by Specific Binding to Downregulated Immune Regulators Vsig4 and IL22ra2.
He S, et al. · Advanced Healthcare Materials · thymosin beta-4-loaded dissolving microneedle patches in a wound-healing model
Thymosin beta-4 delivered by low-temperature-fabricated soluble microneedles promoted wound healing, with the effect linked to binding of the downregulated immune regulators Vsig4 and IL22ra2.
- 10حيواني داخل الجسم الحي2025
Tb4-Engineered ADSC Extracellular Vesicles Rescue Cell Senescence Through Separable Microneedle Patches for Diabetic Wound Healing.
Ding Y, et al. · Advanced Science · diabetic wound model treated with thymosin beta-4-engineered adipose stem cell extracellular vesicles in separable microneedle patches
Extracellular vesicles from thymosin beta-4-engineered adipose-derived stem cells, delivered by separable microneedle patches, reduced cell senescence and improved diabetic wound healing.
- 11حيواني داخل الجسم الحي2024
Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro.
Rahaman KA, et al. · Journal of Chromatography B · in vitro metabolic incubations and rat dosing with UHPLC-Q-Exactive orbitrap MS/MS quantification, plus in vitro wound-healing screening
TB-500 and its metabolites were quantified in vitro and in rats and screened for wound-healing activity. The paper is one of the few to characterise TB-500 disposition rather than assume it matches full-length thymosin beta-4.
- 12حيواني داخل الجسم الحي2021
In situ mucoadhesive hydrogel capturing tripeptide KPV: the anti-inflammatory, antibacterial and repairing effect on chemotherapy-induced oral mucositis.
Shao W, et al. · Biomaterials Science · thermosensitive PLGA-PEG-PLGA hydrogel with EGCG delivering KPV in chemotherapy-induced oral mucositis
A mucoadhesive in situ hydrogel loaded with KPV was developed and evaluated for anti-inflammatory, antibacterial and mucosal repair effects in chemotherapy-induced oral mucositis.
- 13حيواني داخل الجسم الحي2015
Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro.
Huang T, et al. · Drug Design, Development and Therapy · alkali burn rat skin model with topical BPC-157, plus in vitro proliferation, migration and angiogenesis assays
Topical BPC-157 accelerated wound closure after alkali burn, with better granulation tissue formation, re-epithelialisation, dermal remodelling and collagen deposition than controls at day 18, and increased VEGF expression in wounded skin. This is the principal cutaneous animal evidence for BPC-157.
- 14في المختبر2025
Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-kB pathway.
Sung J, et al. · Tissue and Cell · human HaCaT keratinocytes exposed to PM10 particulate matter
KPV at 50 ug/mL restored HaCaT viability and reduced IL-1beta secretion after PM10 exposure, and inhibited reactive oxygen species production upstream of ERK and p38 MAPK activation. The work is entirely cell-culture based.
- 15مراجعة2026
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.
Mendias CL, et al. · Sports Medicine · review of approved and unapproved peptide therapies used for musculoskeletal injury and performance
The review appraised the safety and efficacy evidence for peptides marketed for musculoskeletal and performance use, a category that includes BPC-157 and TB-500. It is one of the most recent independent appraisals of the class.
نتيجة سلامة مُبلغ عنها. Addresses the safety of unapproved peptide therapies used outside regulatory oversight.
- 16مراجعة2026
From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management.
Yuan C, et al. · International Journal of Molecular Sciences · narrative review of BPC-157 in tissue repair and pain
The review summarised proposed mechanisms for BPC-157 across tissue repair and analgesia. The underlying primary literature it draws on is overwhelmingly rodent-based.
- 17مراجعة2012
The regenerative peptide thymosin b4 accelerates the rate of dermal healing in preclinical animal models and in patients.
Treadwell T, et al. · Annals of the New York Academy of Sciences · review of thymosin beta-4 full-thickness punch wound studies in normal, steroid-treated, diabetic and aged rodents, plus two phase 2 clinical trials
Thymosin beta-4 accelerated dermal healing across several rodent models, and in two phase 2 trials of stasis and pressure ulcers accelerated healing by almost a month among those patients who did heal. The qualifier that the benefit applied only to patients who healed is an important limitation.
- 18مراجعة2008
Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases.
Brzoska T, et al. · Endocrine Reviews · comprehensive review of alpha-MSH and its C-terminal tripeptides including KPV
This is the foundational review establishing that the alpha-MSH C-terminal tripeptide KPV retains anti-inflammatory activity in vitro and in vivo without the pigmentary activity of the full hormone. It defines the mechanistic rationale for KPV in inflammatory skin conditions.
ما لا تثبته هذه الأدلة.
No study of the KLOW four-peptide combination exists in any species, so there is no evidence on additive or interfering effects, no combined pharmacokinetics, no dosing rationale and no combination safety data. BPC-157 has never been tested in an adequately powered randomised controlled trial in humans; the only human data are two uncontrolled pilots (n=2 and n=12) published in a low-impact journal, one using compounded product. TB-500 is not identical to thymosin beta-4, and the phase 2 wound trials were conducted with full-length thymosin beta-4 rather than the fragment sold as TB-500. KPV has no published human trial in dermatology. None of these peptides is an approved medicine for a skin indication.
أسئلة شائعة حول البحث.
- What is the research rationale for combining these four peptides?
The components occupy complementary niches in the repair literature: BPC-157 is studied for fibroblast migration and vascular recruitment, TB-500 for actin-mediated cell motility, GHK-Cu for collagen synthesis and matrix remodelling, and KPV for inflammation resolution. Blend vials exist because these mechanisms are frequently co-studied.
- Has the four-peptide KLOW combination been studied?
No. A systematic search of PubMed and Europe PMC returned no published study of the four-peptide blend in any model or species. There is no combined pharmacokinetic data, no evidence on additive or interfering effects, no dosing rationale and no combination safety data. Only one published study examines any two of the four components together.
- What did the one study of two KLOW components together report?
A 2026 experiment in 32 male Sprague-Dawley rats with Achilles tendon transection and repair compared a control group, BPC-157, TB-500 and a combination arm, with intraperitoneal dosing over four weeks. Tendons were assessed by maximum load to failure and by histological, histochemical and immunohistochemical analysis. The authors reported that combined treatment did not confer additional benefit over either peptide given alone.
- How mature is the evidence for the individual KLOW components?
It varies widely, and none of the four is an approved medicine for a skin indication. BPC-157 rests almost entirely on rodent work from a small number of closely affiliated laboratories, with human data limited to two uncontrolled pilot studies of 2 and 12 participants. Full-length thymosin beta-4 has two randomised phase 2 wound trials, but TB-500 is not identical to it and those trials used the full-length peptide. KPV is supported by in vitro and animal anti-inflammatory work with no published human dermatology trial, and the controlled human evidence for GHK-Cu is thin and inconsistent.
متاح من كتالوجنا
لأغراض البحث فقط. ليس للاستهلاك البشري أو التشخيص أو العلاج أو الوقاية من أي حالة. لا شيء في هذه الصفحة يعتبر نصيحة طبية، ولا ينبغي قراءة أي دراسة ملخصة هنا كتوصية.